These data are inclusive of the orally bio-available selective FGFR1–3 inhibitor, pemigatinib, which was the first targeted therapy approved by the Food and Drug Administration in 2020 for the treatment of ICC after progression on gemcitabine-based regimens. The gene discussed is FGFR1; the disease is intrahepatic cholangiocarcinoma.